Last reviewed · How we verify

Manjunath Prakash Pai — Portfolio Competitive Intelligence Brief

Manjunath Prakash Pai pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Voriconazole low dose Voriconazole low dose marketed Triazole antifungal Lanosterol 14α-demethylase (CYP51) Infectious Disease
Voriconazole high dose Voriconazole high dose marketed Triazole antifungal Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 1 shared drug class
  2. Cedars-Sinai Medical Center · 1 shared drug class
  3. Instituto de Investigación Hospital Universitario La Paz · 1 shared drug class
  4. Janssen Pharmaceutical K.K. · 1 shared drug class
  5. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. Pfizer · 1 shared drug class
  8. Seoul National University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Manjunath Prakash Pai:

Cite this brief

Drug Landscape (2026). Manjunath Prakash Pai — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/manjunath-prakash-pai. Accessed 2026-05-16.

Related